GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly ... many of the risk factors of a ...

(NewMediaWire) - November 11, 2024 - DALLAS GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications ... factors of a stroke are also associated with other forms of heart disease," ...

we have seen from randomized controlled trials that SGLT2 inhibitors and GLP-1 receptor agonists have the ability to reduce the risk of cardiovascular disease, which includes stroke, heart attack ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial ...

A new study has found that SGLT-2 inhibitor drugs for type 2 diabetes may also reduce the risk of kidney stones and gout. These painful conditions are ...

Introduction: The development of atrial fibrillation (AF) in patients with heart failure (HF) is associated with increased morbidity and mortality. Initially developed as a diabetic medication, SGLT-2 ...

The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications ... heart patients who have a normal pumping ability. Heart disease, Type 2 diabetes, high blood pressure and obesity ...

A recent study has shown that the weight-loss drug Ozempic, along with other medications in its class, may significantly ...